Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18516917 | 0.83 | CCR1 (0.43) | CCR1CCR8NOS3NOS2ALDH1A1 | |
| SCHEMBL22375286 | 0.83 | KCNH2 (0.39) | CCR1CCR8NOS3NOS2HSD17B10 | |
| SCHEMBL12943016 | 0.81 | PGK1 (0.31) | HPGDCYP3A4TSHR | |
| SCHEMBL20442158 | 0.79 | MEN1 (0.39) | HSD17B10P2RX7RAB9AMEN1KMT2A | |
| SCHEMBL26326025 | 0.78 | KCNH2 (0.41) | CCR1CCR8NOS3NOS2HSD17B10 | |
| SCHEMBL22375312 | 0.78 | KCNH2 (0.41) | CCR1CCR8NOS3NOS2HSD17B10 | |
| SCHEMBL958741 | 0.78 | CCR1 (0.50) | CCR1CCR8NOS3NOS2ALDH1A1 | |
| SCHEMBL13821747 | 0.78 | CCR1 (0.50) | CCR1CCR8NOS3NOS2ALDH1A1 | |
| SCHEMBL77262 | 0.78 | CCR1 (0.50) | CCR1CCR8NOS3NOS2ALDH1A1 | |
| SCHEMBL29380771 | 0.78 | CCR1 (0.50) | CCR1CCR8NOS3NOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MONASH UNIVERSITY | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | CCR1 447/4885CCR8 243/4885NOS3 4021/4885 |
| US-20120259094-A1 | AFFINITY LIGANDS AND METHODS FOR PROTEIN PURIFICATION | MAX, SPR, CCL2 | CCR1 113/4885CCR8 925/4885NOS3 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.